<p>Tiziana Life Sciences Ltd（纳斯达克：TLSA - 获取免费报告）周三的股价上涨了 0.7%。该股票最高交易价为 1.4099 美元，最后交易价为 1.40 美元。当天中午交易中，共交易了 76,328 股，较平均交易量 195,954 股下降了 61%。该股票此前收盘价为 1.39 美元。</p>
<p>获取 <strong>Tiziana Life Sciences</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<p>另外，Weiss Ratings 在 1 月 21 日的报告中重新发布了对 Tiziana Life Sciences 股票的 “卖出（d-）” 评级。一位研究分析师对该股票给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级目前为 “卖出”。</p>
<p><strong>获取我们最新的 TLSA 股票分析</strong></p>
<h2>Tiziana Life Sciences 股票表现</h2>
<p>该公司的 50 日移动平均线为 1.51 美元，200 日移动平均线为 1.76 美元。</p>
<h2>机构投资者对 Tiziana Life Sciences 的看法</h2>
<p>一些机构投资者和对冲基金最近对 TLSA 的持仓进行了调整。Rachor Investment Advisory Services LLC 在第四季度收购了 Tiziana Life Sciences 的新股份，价值约 25,000 美元。Cubist Systematic Strategies LLC 在第一季度收购了 Tiziana Life Sciences 的新股份，价值约 25,000 美元。Marshall Wace LLP 在第二季度收购了 Tiziana Life Sciences 的新股份，价值约 39,000 美元。HRT Financial LP 在第四季度购买了 Tiziana Life Sciences 的新头寸，价值约 36,000 美元。最后，ARS Investment Partners LLC 在第三季度收购了 Tiziana Life Sciences 的新头寸，价值 66,000 美元。</p>
<h2>关于 Tiziana Life Sciences</h2>
<p>（获取免费报告）</p>
<p>Tiziana Life Sciences plc（纳斯达克：TLSA）是一家临床阶段的生物技术公司，专注于在肿瘤学、免疫学和传染病领域开发新型治疗药物。公司总部位于伦敦，在马萨诸塞州剑桥市设有研发机构，致力于推进小分子抑制剂和单克隆抗体候选药物的研发，旨在调节免疫通路和靶向肿瘤生长。</p>
<p>该公司的主要小分子项目 milciclib 是一种口服细胞周期依赖性激酶抑制剂，目前正在进行针对肝细胞癌和某些神经内分泌肿瘤的二期临床试验。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Tiziana Life Sciences</li>
<li>有 500 美元？投资于埃隆的人工智能大师计划</li>
<li>你的银行账户不再安全</li>
<li>白银支付 20% 的股息，外加 68% 的股价上涨</li>
<li>美联储刚刚遭遇重创——接下来会发生什么</li>
<li>这只 15 美元的股票可能会成为 2026 年的第一只股票</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元于 Tiziana Life Sciences 吗？</h2>
<p>在考虑 Tiziana Life Sciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Tiziana Life Sciences 并不在名单上。</p>
<p>虽然 Tiziana Life Sciences 目前在分析师中被评为卖出，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

医疗业 ETF - Vanguard

医疗业 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Tiziana Life Sciences（纳斯达克代码：TLSA）股价在交易中上涨 0.7%，至 1.40 美元，成交量较平均水平下降 61%。分析师对该股票给予 “卖出” 评级，Weiss Ratings 重申了 “卖出（d-）” 评级。机构投资者最近已在该公司中获得股份，该公司专注于开发肿瘤学和传染病的治疗药物。尽管股价略有上涨，但并不受到顶级分析师的青睐，他们推荐其他股票</p>

<p>Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report)'s share price shot up 0.7% during trading on Wednesday . The stock traded as high as $1.4099 and last traded at $1.40. 76,328 shares were traded during mid-day trading, a decline of 61% from the average session volume of 195,954 shares. The stock had previously closed at $1.39.</p>
<div class="lb-trans"><p>Tiziana Life Sciences Ltd（纳斯达克：TLSA - 获取免费报告）周三的股价上涨了 0.7%。该股票最高交易价为 1.4099 美元，最后交易价为 1.40 美元。当天中午交易中，共交易了 76,328 股，较平均交易量 195,954 股下降了 61%。该股票此前收盘价为 1.39 美元。</p>
</div><p>Get <strong>Tiziana Life Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Tiziana Life Sciences</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Separately, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Tiziana Life Sciences in a report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 1 月 21 日的报告中重新发布了对 Tiziana Life Sciences 股票的 “卖出（d-）” 评级。一位研究分析师对该股票给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级目前为 “卖出”。</p>
</div><p><strong>Get Our Latest Stock Analysis on TLSA</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 TLSA 股票分析</strong></p>
</div><h2>Tiziana Life Sciences Stock Performance</h2>
<div class="lb-trans"><h2>Tiziana Life Sciences 股票表现</h2>
</div><p>The firm's 50-day moving average is $1.51 and its two-hundred day moving average is $1.76.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 1.51 美元，200 日移动平均线为 1.76 美元。</p>
</div><h2>Institutional Investors Weigh In On Tiziana Life Sciences</h2>
<div class="lb-trans"><h2>机构投资者对 Tiziana Life Sciences 的看法</h2>
</div><p>A number of institutional investors and hedge funds have recently made changes to their positions in TLSA. Rachor Investment Advisory Services LLC acquired a new stake in shares of Tiziana Life Sciences during the fourth quarter worth about $25,000. Cubist Systematic Strategies LLC acquired a new stake in Tiziana Life Sciences during the 1st quarter worth approximately $25,000. Marshall Wace LLP acquired a new stake in Tiziana Life Sciences during the 2nd quarter worth approximately $39,000. HRT Financial LP purchased a new position in Tiziana Life Sciences in the 4th quarter valued at approximately $36,000. Finally, ARS Investment Partners LLC acquired a new position in shares of Tiziana Life Sciences in the third quarter worth $66,000.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近对 TLSA 的持仓进行了调整。Rachor Investment Advisory Services LLC 在第四季度收购了 Tiziana Life Sciences 的新股份，价值约 25,000 美元。Cubist Systematic Strategies LLC 在第一季度收购了 Tiziana Life Sciences 的新股份，价值约 25,000 美元。Marshall Wace LLP 在第二季度收购了 Tiziana Life Sciences 的新股份，价值约 39,000 美元。HRT Financial LP 在第四季度购买了 Tiziana Life Sciences 的新头寸，价值约 36,000 美元。最后，ARS Investment Partners LLC 在第三季度收购了 Tiziana Life Sciences 的新头寸，价值 66,000 美元。</p>
</div><h2>About Tiziana Life Sciences</h2>
<div class="lb-trans"><h2>关于 Tiziana Life Sciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Tiziana Life Sciences plc NASDAQ: TLSA is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.</p>
<div class="lb-trans"><p>Tiziana Life Sciences plc（纳斯达克：TLSA）是一家临床阶段的生物技术公司，专注于在肿瘤学、免疫学和传染病领域开发新型治疗药物。公司总部位于伦敦，在马萨诸塞州剑桥市设有研发机构，致力于推进小分子抑制剂和单克隆抗体候选药物的研发，旨在调节免疫通路和靶向肿瘤生长。</p>
</div><p>The company's lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.</p>
<div class="lb-trans"><p>该公司的主要小分子项目 milciclib 是一种口服细胞周期依赖性激酶抑制剂，目前正在进行针对肝细胞癌和某些神经内分泌肿瘤的二期临床试验。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Tiziana Life Sciences</li>
<li>Have $500? Invest in Elon’s AI Masterplan</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Silver paying 20% dividend. Plus 68% share gains</li>
<li>The Fed Just Got Kneecapped — Here’s What Happens Next</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Tiziana Life Sciences</li>
<li>有 500 美元？投资于埃隆的人工智能大师计划</li>
<li>你的银行账户不再安全</li>
<li>白银支付 20% 的股息，外加 68% 的股价上涨</li>
<li>美联储刚刚遭遇重创——接下来会发生什么</li>
<li>这只 15 美元的股票可能会成为 2026 年的第一只股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tiziana Life Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于 Tiziana Life Sciences 吗？</h2>
</div><p>Before you consider Tiziana Life Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Tiziana Life Sciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Tiziana Life Sciences 并不在名单上。</p>
</div><p>While Tiziana Life Sciences currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Tiziana Life Sciences 目前在分析师中被评为卖出，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Tiziana Life Sciences（NASDAQ:TLSA）股价上涨 0.7% - 事情经过如下